Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study,
|
|
- Piers Bradley
- 6 years ago
- Views:
Transcription
1 DOI: / j x HIV Medicine (2008), 9, ORIGINAL RESEARCH r 2008 British HIV Association Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, A Nguyen, 1 A Calmy, 1 V Schiffer, 1 E Bernasconi, 2 M Battegay, 3 M Opravil, 4 J-M Evison, 5 PE Tarr, 6 P Schmid, 7 T Perneger, 8 B Hirschel 1 and the Swiss HIV Cohort Study* 1 Infectious Disease/HIV Unit, University Hospital Geneva, Geneva, Switzerland, 2 Infectious Disease Service, Hospital Lugano, Lugano, Switzerland, 3 Division of Infectious Diseases, University Hospital Basel, Basel, Switzerland, 4 Division of Infectious Diseases, University Hospital Zurich, Zurich, Switzerland, 5 Infectious Disease Service, University Hospital Bern, Bern, Switzerland, 6 Infectious Disease Service, University Hospital Lausanne, Lausanne, Switzerland, 7 Infectious Disease Unit, Hospital St-Gall, St-Gall, Switzerland and 8 Quality of Care Service, University Hospital Geneva, Geneva, Switzerland Background and Objectives Combination antiretroviral therapy (cart) is changing, and this may affect the type and occurrence of side effects. We examined the frequency of lipodystrophy (LD) and weight changes in relation to the use of specific drugs in the Swiss HIV Cohort Study (SHCS). Methods In the SHCS, patients are followed twice a year and scored by the treating physician as having fat accumulation, fat loss, or neither. Treatments, and reasons for change thereof, are recorded. Our study sample included all patients treated with cart between 2003 and 2006 and, in addition, all patients who started cart between 2000 and Results From 2003 to 2006, the percentage of patients taking stavudine, didanosine and nelfinavir decreased, the percentage taking lopinavir, nevirapine and efavirenz remained stable, and the percentage taking atazanavir and tenofovir increased by 18.7 and 22.2%, respectively. In life-table Kaplan Meier analysis, patients starting cart in were less likely to develop LDthanthosestarting cartfrom2000to2002(po0.02). LD was quoted as the reason for treatment change or discontinuation for 4% of patients on cart in 2003, and for 1% of patients treated in 2006 (P for trend o0.001). In univariate and multivariate regression analysis, patients with a weight gain of 5 kg were more likely to take lopinavir or atazanavir than patients without such a weight gain [odds ratio (OR) 2, 95% confidence interval (CI) , and OR 1.7, 95% CI , respectively]. Conclusions LD has become less frequent in the SHCS from 2000 to A weight gain of more than 5 kg was associated with the use of atazanavir and lopinavir. Keywords: antiretroviral therapy, body weight, cohort studies, fat accumulation, fat loss, lipodystrophy, nonnucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease inhibitors, Swiss HIV Cohort Study Received: 8 October 2007, accepted 6 November 2007 Introduction Combination antiretroviral therapy (cart) against HIV infection has diminished AIDS-related morbidity and *All investigators are listed in the Appendix. Correspondence: Dr Alexandra Calmy, Division des Maladies infectieuses, Geneva University Hospital, rue Micheli-du-Crest 24, 1211 Genève 14, Switzerland. Tel: ; fax: ; acalmy@gmail.com mortality [1]. Suppression of viral replication to below the detection level has become a treatment goal that can also be reached for patients with triple class treatment failure. However, patients on cart often develop long-term side effects, particularly lipodystrophy (LD) syndrome, a combination of fat atrophy (in the limbs, buttocks and face) and visceral fat accumulation, with or without lipid and glucose metabolism disturbances [2 4]. The definition of LD remains a challenge [39]. Proposals for a case definition 142
2 Lipodystrophy and weight changes in the SHCS 143 have been put forward, but necessitate dual energy x-ray absorptiometry (DEXA) and computed tomography (CT) scans [3 7]; while invaluable for small-scale studies, they are not practical for routine use in patients. Instead, larger cohorts and epidemiological studies most often rely only on the subjective impressions of patients and/or physicians [8]. LD may decrease compliance with therapy for aesthetic reasons [9], but also may be associated with an increased risk of cardiovascular diseases [5,9], insulin resistance [10,11], and diabetes [6,12,13]. The aetiology of LD in HIV-infected patients is still unclear [3 7]. LD was initially attributed to prolonged therapy with protease inhibitors (PIs) [14 16], but all current drug classes have been involved in LD [17 19]. Lipoatrophy is related to the mitochondrial toxicity of nucleoside reverse transcriptase inhibitors (NRTIs), whose action is not limited to inhibition of reverse transcription, but extends to mitochondrial DNA polymerase g, the main enzyme involved in replication of mitochondrial DNA. Inhibition of this enzyme is associated with abnormal mitochondrial morphology and may induce apoptosis of adipocytes and lipoatrophy [20,21]. In contrast, the pathogenesis of fat accumulation is not clear. Proposed mechanisms abound: highly active antiretroviral therapy (HAART) may have an impact on cytokines and cytokine receptors [22] and appetite regulators [23], as well as on the differentiation and functions of the adipocytes [20,21,24] and growth hormone metabolism [25,26]. Another theory holds that abdominal and visceral fat accumulation is a consequence of lipoatrophy, because the atrophic fatty tissues are unable to take up fat from the plasma [4]. Of note, a pure phenotype of fat atrophy or fat accumulation is only seen in 10% of patients. The paradox that central fat increases while subcutaneous fat decreases can be explained by the difference between visceral fat (mainly comprising brown adipocytes) and subcutaneous fat (comprising mainly white adipocytes): thus exposure to antiretrovirals may affect subcutaneous adipose tissue differently from visceral adipose tissue [27]. Because HAART entails the combined use of several drugs, it has been difficult to link the various manifestations of LD to a particular molecule. Cross-sectional and prospective studies demonstrated that stavudine (d4t) was the drug most frequently associated with fat atrophy [28,29]. Other risk factors include race, age and HIV disease severity for fat atrophy, and race, sex and sedentary lifestyle for fat accumulation [4]. The present paper attempts to analyse these data in relation to the type of cart administered. It focuses on the period from 2003 to 2006, coincident with the introduction of atazanavir (ATV) and the introduction of new NRTIs. Patients and methods The Swiss HIV Cohort Study (SHCS) is a nationwide prospective study based on voluntary participation of persons infected with HIV-1. The rationale, organization and baseline characteristics of the study have been described elsewhere in detail [30], and a continuously updated description can be found at the Swiss HIV Cohort website [31]. LD is coded based on the subjective impression of the treating physician as fat accumulation or fat loss, and is routinely recorded 6-monthly in the SHCS database. More objective measurements, such as DEXA scans or computed tomography (CT) scans, were not available for this study. Incidence of LD in patients starting cart All study participants who had previously been antiretroviral-naïve, but who started cart between 1 January 2000 and 31 December 2006, were eligible for inclusion. The time to the occurrence of fat loss or fat accumulation, or a treatment change because of LD noted at one of the 6-monthly cohort visits, was measured according to Kaplan Meier. Two groups were compared with the logrank test: patients starting cart between 2000 and 2002 and patients starting cart between 2003 and Prevalence of weight changes, fat loss and fat accumulation in patients on cart To establish how frequently antiretroviral treatment was changed because of fat loss or fat accumulation, we included all patients on cart with at least one follow-up visit between 2003 and The number of patients on cart with a discontinuation or change of treatment because of fat loss or fat accumulation was determined and related to the total number of patients on cart during the same year, considering only the first change or discontinuation in that year. A P-trend analysis for the prevalence of discontinuation or change in general, and the prevalence of discontinuation or change in particular because of fat loss or fat accumulation, was performed. Analysis of factors associated with weight gain, weight loss, fat loss and fat accumulation In order to analyse factors associated with gain of weight, patients who gained 5 kg between two consecutive visits were compared with patients who did not have such gain of weight. In order to exclude from consideration the weight gain corresponding to correction of AIDS-related cachexia,
3 144 A Nguyen et al. we included in this analysis only patients with a baseline body mass index (BMI) above 20 for men and above 18 for women. Factors associated with a weight gain 5 kg between the first two follow-up cohort visits between 2003 and 2006 were examined using univariate analysis followed by multivariate logistic regression. Gender, ethnic origin, diabetes status based on the guidelines of the American Diabetes Association (ADA) [32], smoking status and cart (current exposure, i.e. cart received during the period when weight changed or fat loss/accumulation occurred) were entered as categorical variables; for age, BMI, CD4 cell count, RNA viral load, plasma cholesterol (mmol/l), and triglyceride (mmol/l), quartiles were compared (see Table 1). The baseline was defined as the first visit of the first two follow-up cohort visits between 2003 and The multivariate model was constructed using the forward stepwise approach, including covariates that remained significant at the 0.1 level in univariate analysis. We repeated the analysis for factors associated with weight loss, fat accumulation and fat loss. Analyses were performed using the SPSS version 11.0 for Windows statistical software package (SPSS Inc., Chicago, IL, USA). Results Use of antiretroviral drugs in SHCS, In each year from 2000 to 2006, between 5203 and 6016 patients had a follow-up visit in the SHCS. Figure 1 shows the proportion of patients treated with the 10 most frequently used drugs, plus d4t. Between 2003 and 2006, use of zidovudine (ZDV), lamivudine (3TC), didanosine (ddi) and d4t declined, use of lopinavir (LPV), abacavir (ABC), efavirenz (EFV) and nevirapine (NVP) remained stable, and use of ATV, emtricitabine (ETC) and tenofovir (TDF) increased by 18.7, 8.2 and 22.2%, respectively. Incidence of LD in treatment-naïve patients Figure 2 shows the likelihood of occurrence of LD in patients who were cart-naïve, and started treatment between 2000 and Patients starting treatment in were significantly less likely to experience LD than those starting between 2000 and 2002 (log rank ). From 2000 to 2002, most patients were started on 3TC (96.9%), ZDV (88.5%), d4t (4.2%), TDF (0.8%), EFV (38.1%), nelfinavir (NFV) (28.8%) and LPV (13.8). From 2003 to 2006, the corresponding percentages were 83.7% for 3TC, 10.8% for ETC, 64.2% for ZDV, 0.7% for d4t, 30.5% for TDF, 41.8% for EFV, 3.8% for NFV, Table 1 Baseline characteristics of patients Population characteristics: demographic Female gender 32.2 Age (years) Ethnic origin w White 82.6 Black 12.0 Hispano-American 2.0 Asian 3.0 Body mass index* o cart use Zidovudine 54.2 Abacavir 24.3 Stavudine 14.3 Didanosine 15.8 Atazanavir 5 Lopinavir 22.4 Indinavir 3.7 Nelfinavir 15.9 Efavirenz 30.2 Nevirapine 10 Population characteristics: laboratory variables CD4 (cells/ml) RNA viral load (log copies/ml) o and o and o Cholesterol (mmol/l) 1.2 and o and o and o Triglycerides (mmol/l) 0.2 and o and o and o Current smoker 46.7 Diabetes mellitus 0.5 Fat loss without fat accumulation 10.4 Fat accumulation without fat loss 12.3 Fat loss and fat accumulation 10.3 combined Baseline value for physician visit in (n patients) (%) Baseline value for physician visit in (n patients) (%) cart, combination antiretroviral therapy; *2% of population had unknown heights, thus BMI was not available; w 0.4% of population had unknown ethnic origins.
4 Lipodystrophy and weight changes in the SHCS Percentage of patients TC ZDV EFV ABC LPV ddi NVP d4t ATV ETC TDF Antiretroviral drugs Fig. 1 Proportion of patients treated with frequently used antiretroviral drugs in TC, lamivudine; ABC, abacavir; ATV, atazanavir; d4t, stavudine; ddi, didanosine; EFV, efavirenz; ETC, emtricitabine; LPV, lopinavir; NVP, nevirapine; TDF, tenofovir; ZDV, zidovudine..4 Probability of developing lipodystrophy Patients starting cart between 2000 and 2002 (n = 475, mean survival time = 4.89 years) Patients starting cart between 2003 and 2006 (n = 721, mean survival time = 3.16 years) Time (years) Fig. 2 Probability of developing lipodystrophy since 2000 for the groups of naïve patients starting combination antiretroviral therapy (cart) in and , respectively. 38.5% for LPV and 7.5% for ATV. Overall, the proportion of patients initiating cart with ATV, ritonavir-boosted LPV (LPV/r) or TDF was higher in the period than in the period. Treatment changes because of LD A total of 5777 patients were followed in the SHCS in 2003, and 6016 during Baseline characteristics are summarized in Table 1: 32% of the patients were female, and they had a median age of 42.5 years [interquartile range (IQR) years]. The number of patients treated with carts was 5269 (91.2%) in 2003 and 5530 (91.9%) in In 2003, 44% underwent a change or discontinuation of treatment, while in 2006 the proportion decreased to 17% (Po0.001). LD was quoted as the reason for treatment change or discontinuation for 4% of patients on carts in 2003, but for only 1% of patients treated in 2006 (P for trend o0.001). 10.4% of patients were diagnosed with only fat loss and 12.3% with only fat accumulation. Overall, 33.9% had a diagnosis of either fat loss and fat accumulation or fat loss or fat accumulation. We determined the proportion of patients who had a fat loss or a fat accumulation diagnosis before our baseline. 90.4% of ABC-treated patients diagnosed with fat accumulation and 93.4% of those diagnosed with fat loss had had this diagnosis for more than 2 years. For ZDV-treated patients, we observed similar results (83.1% for fat accumulation and 86.4% for fat loss). Factors involved in weight changes and fat redistribution (see Tables 2 and 3) Weight changes Weight gain of 5kg The mean BMI of our population was 23.7 kg/m 2. In 2003, of the patients with eligible BMIs (418 kg/m 2 ), 494 (7.03%)
5 146 A Nguyen et al. Table 2 Univariate analysis of factors associated with weight gain, weight loss and lipodystrophy* Weight gain 5 kg Weight loss 5 kg Fat accumulation Fat loss Characteristic OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value Female gender Age (years) Body mass index o Ethnic origin White 1.0 Black Hispano-American Asian Smoking Diabetes CD4 (cells/ml) Plasma HIV RNA (log copies/ml) o and o and o Total cholesterol (mmol/l) 1.2 ando ando ando Triglycerides (mmol/l) 0.2 ando ando and o Drugs Zidovudine Abacavir Stavudine Didanosine Atazanavir Lopinavir Indinavir Nelfinavir Efavirenz Nevirapine CI, confidence interval; OR, odds ratio; *values in bold indicate P-value experienced a rapid gain of weight of 5 kg within a 6-month period, as compared with 491 (6.49%) in 2004, 517 (6.57%) in 2005, and 222 (5.51%) in 2006 (difference not significant). Diabetes [odds ratio (OR) 3.4, Po0.01], viral load 4.3 log HIV-1 RNA copies/ml (OR 2.1, Po0.001), ATV (OR 1.7, Po0.001) and LPV/r (OR 2.4, Po0.001) use, and BMI o25 and 430 (OR 1.5, Po0.001) were associated with a 5kg weight gain (Table 2). Age above 37 years, a CD4 count 4300 cells/ml, a plasma cholesterol value 5 mmol/l and the use of ABC (OR 0.7, Po0.01) were associated with a lower probability of weight gain. In multivariate analysis, ATV (OR 2, P ) and LPV/r (OR 1.7, Po0.001) were associated with weight gain. A high CD4 cell count was a protective factor for weight gain (OR 0.6, Po0.001), being associated with a lower probability of weight gain (see
6 Lipodystrophy and weight changes in the SHCS 147 Table 3 Multivariate analysis of factors associated with weight gain, weight loss and lipodystrophy [lipoatrophy (fat loss) and lipohypertrophy (fat gain)] Weight gain 5 kg Weight loss 5 kg Fat accumulation Fat loss Characteristic OR P-value OR P-value OR P-value OR P-value Drugs Zidovudine o0.001 Abacavir 1.35 o0.001 Stavudine Didanosine Atazanavir Lopinavir 1.65 o0.001 Indinavir Nelfinavir Efavirenz Nevirapine Female gender Age (years) o o o o o o0.001 Ethnic origin White Black 1.74 o o0.001 Hispano-American Asian Current smoker Diabetes mellitus CD4 (cells/ml) o o o o o0.001 RNA viral load (log copies/ml) o and o and o o o0.001 OR, odds ratio. Table 3). Patients who gained 45 kg had a mean BMI of 25.4 (after weight gain), compared with 23.6 in patients who gained o5 kg (Table 3). Weight loss of 45kg A CD4 count 4300 cells/ml (OR 0.7, Po0.03), a cholesterol value 5 mmol/l (OR 0.7, Po0.1) and EFV use (OR 0.7, Po0.03) were associated with a lower probability of weight loss 5 kg, while smoking (OR 1.5, Po0.001), plasma HIV RNA 4.3 log copies/ml (OR 1.4, Po0.02) and trigylceride values o1.75 mmol/l (OR 1.3, Po0.1) were associated with loss of weight (Table 2). In multivariate analysis, female gender (OR 1.3, P ) and smoking (OR 1.5, Po0.001) were associated with increased risk of weight loss, while a high CD4 count 4300 cells/ml (OR 0.7, P ) was protective for weight loss (Table 3). Fat distribution Fat accumulation (lipohypertrophy) Older age (OR 3, Po0.001), white ethnic origin (OR 1.3, Po0.01), diabetes (OR 3.2, Po0.01), CD4 count 4300 cells/ml (OR 1.5, Po0.001), cholesterol values 5 mmol/l (OR 1.3, Po0.01), triglyceride values 1.75 mmol/l (OR 1.7, Po0.001), and ABC (OR 1.5, Po0.001), IDV (OR 1.9, Po0.001), NFV (OR 1.7, Po0.001) and EFV use (OR 1.4, P ) were associated with the presence of fat accumulation. Smoking (OR 0.7, Po0.001), RNA viral load 4.3 log copies/ml (OR 0.5, Po0.001) and ZDV use (OR 0.8, Po0.02) were associated with less reported fat accumulation (Table 2). In multivariate analysis, older age (OR 3.2, Po0.001), black ethnic origin (OR 1.7, Po0.001), high CD4 cell count (OR 1.3, Po0.02) and NFV use (OR 1.4, P ) predicted the presence of lipohypertrophy. Being a smoker (OR 0.8,
7 148 A Nguyen et al. P ), having a high RNA viral load (44.3 log copies/ ml, Po0.001) or being on ZDV (OR 0.8, P ) was associated with less fat accumulation (Table 3). Fat loss (lipoatrophy) Older age (OR 4.2, Po0.001), a higher CD4 cell count (OR 1.9, Po0.001), a higher cholesterol value (OR 2.1, Po0.001), a higher triglyceride value (OR 3.9, Po0.001), and ABC (OR 1.8, Po0.001), ATV (OR 1.2, Po0.03), NFV (OR 1.4, Po0.01) and EFV (OR 1.3, Po0.01) use were associated with greater lipoatrophy. BMI 425 and o30 (OR 0.8, Po0.002), black ethnicity (OR 0.3, Po0.001) and Asian ethnicity (OR 0.5, Po0.01), viral load 4.3 log copies/ml (OR 0.4, Po0.001), and ZDV (OR 0.5, Po0.001) and LPV (OR 0.7, Po0.04) use were associated with less atrophy (Table 2). Finally, multivariate analysis showed that lipoatrophy was associated with female gender (OR 1.3, P ), older age (OR 2.5, Po0.001) high CD4 cell count (OR 1.8, Po0.001) and ABC use (OR 1.35, Po0.001). An absence of fat loss was associated with black ethnic origin (OR 0.5, P40.001), high RNA viral load (OR 0.6, Po0.001) and use of ZDV (OR 0.4, Po0.001) (Table 3). Discussion In this study, in which more than 5500 patients were investigated within a large prospective cohort, we found that LD has become less frequent since LD was discovered in the late 1990s, when the most frequently used drugs were d4t and indinavir. By 2006, neither was among the 10 most used antiretrovirals in Switzerland. While the use of thymidine analogues was almost universal in initial treatment in 2000, d4t is no longer recommended in the guidelines for treatment initiation [33] and had nearly disappeared by 2006, whereas ZDV tends to be replaced by TDF. Randomized prospective studies show that lipoatrophy develops less frequently on TDF than on d4t [34]. Randomized studies represent a particular situation and their results are not always reproduced in clinical practice. However, in this instance, when patients who started treatment in the period were compared with those who started treatment later, we found that the probability of developing LD had decreased, while the pattern of drug prescription had significantly changed. In addition, in an analysis of all patients (not just the newly treated), the number of visits resulting in a change of treatment because of LD was found to have steadily decreased from 2003 to This indicates that, in the SHCS, the prevalence of LD serious enough to warrant a change of treatment is decreasing. DEXA scans of patients taking standard NRTI-based cart show an early increase in limb fat before a steady and progressive limb fat loss from 3 months onwards [35]. What will happen when thymidine analogues are no longer used? One may speculate that the atrophic effect on fat tissue will disappear, but that the influence of the other constituents of cart on fat will persist. For instance, if PIs contribute to fat accumulation, their unopposed actions might lead to gain of weight. Our results lend some support to this hypothesis, because substantial weight gain ( 5 kg within 6 months) was indeed associated with the use of the PIs LPV and ATV. By restricting our analysis to patients with a BMI 420 in men, and 418 in women, we attempted to exclude patients where AIDS-related cachexia was corrected through HAART. Nonetheless, it is still unclear whether the weight gain represents an undesirable side effect, or rather the return to desirable normalcy. As expected, the average BMI in weight gainers (25.4) was higher than the average BMI of other patients, but was still lower than the average BMI of American patients [36]. Cohort studies have inherent advantages (for instance, long follow-up and large size) but also disadvantages. Lack of randomization and masking favour bias and confounding. Among other well-known risk factors for lipoatrophy (older age, low CD4 and high HIV RNA), we showed that ABC was associated in both univariate and multivariate analyses with a diagnosis of lipoatrophy. This was puzzling, because randomized trials demonstrated that patients randomized to ABC had greater recovery of limb fat mass compared with those remaining on thymidine analogues [37]. Examination of individual case records in the SHCS revealed that many ABC-treated patients had previously been diagnosed with lipoatrophy, leading to replacement of ZDV or d4t in patients with atrophy [37,38] by ABC; as atrophy persists for years, so does the association with ABC. In the context of this observational cohort, association does not equal causation. Other study limitations include the lack of objective measures for fat loss and fat redistribution. However, SHCS patients are treated by specialized physicians skilled in the detection and the management of LD. Diet or lifestyle variables are not routinely recorded in the database and may limit the ability to interpret weight changes. Moreover, the database does not allow assessment of the use of ritonavir as a booster in ATV-treated patients. In our analysis we made no distinction between current and cumulative exposure to individual ART agents. However, we have demonstrated that LD was generally diagnosed long before inclusion in our analysis in We have scanned the medical literature and conference abstracts to search for other evidence of changing patterns
8 Lipodystrophy and weight changes in the SHCS 149 and incidence of LD, but without success. The preliminary data we report here should stimulate additional research on the prevalence of LD and weight changes in large cohorts. It will be of particular interest to examine the impact of new drug classes, such as integrase or entry inhibitors, on the long-term pattern of fat redistribution and weight changes. References 1 Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: Umeh OC, Currier JS. Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. Curr HIV/AIDS Rep 2005; 2: Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004; 350: Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17 (Suppl. 1): S141 S Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51 F58. 7 Tien PC, Grunfeld C. What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Curr Opin Infect Dis 2004; 17: Mulligan K, Parker RA, Komarow L et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr 2006; 41: Hawkins T. Appearance-related side effects of HIV-1 treatment. AIDS Patient Care STDS 2006; 20: 6 18, Review. 10 Thiébaut R, Daucourt V, Mercié P et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, Clin Infect Dis 2000; 31: Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitorassociated hyperglycaemia. Lancet 1997; 350: Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: Walli R, Herfort O, Michl GM et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12: F167 F Martinez E, Mocroft A, García-Viejo MA et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357: Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 1998; 27: Bonfanti P, Gulisano C, Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. et al. Risk factors for lipodystrophy in the CISAI cohort. Biomed Pharmacother 2003; 57: Seminari E, Tinelli C, Minoli L et al. Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients. Antivir Ther 2002; 7: Haugaard SB. Toxic metabolic syndrome associated with cart. Expert Opin Drug Metab Toxicol 2006; 2: Kosmiski LA, Miller HL, Klemm DJ. In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3-L1 adipocyte lipid accumulation and survival. Antivir Ther 2006; 11: Walker UA, Bickel M, Lutke Volksbeck SI et al. Evidence of nucleoside analogue reverse transcriptase inhibitor associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J AIDS 2002; 29: Shikuma CM, Hu N, Milne C et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15: Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 2002; 16: Arnalich F, Martinez P, Hernanz A et al. Altered concentrations of appetite regulators may contribute to the development and maintenance of HIV-associated wasting. AIDS 1997; 11: Bastard JP, Caron M, Vidal H et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359: Christeff N, Melchior JC, de Truchis P, Perronne C, Nunez EA, Gougeon ML. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999; 13: Rietschel P, Hadigan C, Corcoran C et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001; 86: Mallon PW. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy. AIDS Rev 2007; 9: 3 15.
9 150 A Nguyen et al. 28 Bernasconi E, Boubaker K, Junghans C et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2002; 31: Young J, Rickenbach M, Weber R et al. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based cart in the Swiss HIV cohort study. Antivir Ther 2005; 10: Ledergerber B, von Overbeck J, Egger M, Luthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed 1994; 39: SHCS website available at: 32 American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27 (Suppl. 1): S15 S Hammer SM, Saag MS, International AIDS Society-USA panel et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: Gallant JE, Staszewski S, 903 Study Group et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17: CDC-NHANES available at: (accessed 28 June, 2007) 37 Carr A, Workman C, Mitochondrial Toxicity (MITOX) Study Group et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288: Moyle GJ, Sabin CA, RAVE (Randomized Abacavir versus Viread Evaluation) Group UK et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case control study. Lancet 2003; 361: Appendix: composition of the SHCS cohort The members of the Swiss HIV Cohort Study are M. Battegay, E. Bernasconi, J. Böni, H. Bucher, Ph. Bürgisser, A. Calmy, S. Cattacin, M. Cavassini, R. Dubs, M. Egger, L. Elzi, P. Erb, M. Fischer, M. Flepp, A. Fontana, P. Francioli, H. Furrer, M. Gorgievski, H. Günthard, H. Hirsch, B. Hirschel, I. Hösli, Ch. Kahlert, L. Kaiser, U. Karrer, C. Kind, Th. Klimkait, B. Ledergerber, G. Martinetti, B. Martinez, N. Müller, D. Nadal, M. Opravil, F. Paccaud, G. Pantaleo, M. Rickenbach, C. Rudin, P. Schmid, D. Schultze, J. Schüpbach, R. Speck, P. Taffé, P. Tarr, A. Telenti, A. Trkola, P. Vernazza, R. Weber and S. Yerly. Composition of the University Hospital Geneva Cohort Participating physicians B. Hirschel, V. Schiffer, E. Boffi, S. Inoubli, A. Gayet, C. Morel-Boyce, S. Emonet, A. Calmy and A. Nguyen Database manager A. Nguyen
AIDS 2002, 16:381±385. Keywords: HAART, efavirenz, cohort study, matched case-control study, HIV, HIV protease inhibitors
Switching from protease inhibitors to efavirenz: differences in ef cacy and tolerance among risk groups: a case±control study from the Swiss HIV Cohort Bernard Hirschel a, Markus Flepp b, Heiner C. Bucher
More informationFat redistribution on ARVs: dogma versus data
Fat redistribution on ARVs: dogma versus data Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Half of what we are going to teach
More information(See the editorial commentary by Sasson et al. on pages 373 5)
MAJOR ARTICLE HIV/AIDS Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to!500 Cells/mL in HIV Type 1 Infected Individuals Receiving Potent Antiretroviral Therapy Gilbert R.
More informationTOXICITY, TOLERABILITY, AND ADHERENCE TO THERAPY
SAFETY AND TOLERABILITY OF CURRENTLY AVAILABLE ANTIRETROVIRAL AGENTS * Esteban Martinez, MD, PhD ABSTRACT Safety and tolerability are important factors to consider when instituting or modifying therapy
More informationWhen to Rock the Boat Switching Antiretroviral Therapy for Metabolic Complications
When to Rock the Boat Switching Antiretroviral Therapy for Metabolic Complications 12 th Annual Tennessee AETC/CCC HIV Symposium 6 November 2009 Todd Hulgan, MD, MPH Assistant Professor of Medicine Division
More informationLiver enzyme elevation after lamivudine withdrawal in HIV hepatitis B virus co-infected patients: the Swiss HIV Cohort Study
DOI: 10.1111/j.1468-1293.2008.00646.x HIV Medicine (2009), 10, 12 18 ORIGINAL RESEARCH r 2008 British HIV Association Liver enzyme elevation after lamivudine withdrawal in HIV hepatitis B virus co-infected
More informationHIV and cardiovascular disease
Basel Institute ceb for Clinical Epidemiology and Biostatistics HIV and cardiovascular disease Cardiology update 2013 20 th International Postgraduate Course on Cardiovascular Disease Davos 10-15 February
More informationSelf-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality: Swiss HIV Cohort Study
Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality: Swiss HIV Cohort Study Tracy R. Glass a,b,c, Jonathan A.C. Sterne d, Marie-Paule Schneider e,f, Sabina
More informationLipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV Cohort Study
Research article Antiviral Therapy 1:585 591 Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV Cohort Study Jim Young 1 *, Rainer Weber 2, Martin Rickenbach,
More informationTo interrupt or not to interrupt Are we SMART enough?
SMART To interrupt or not to interrupt Are we SMART enough? highly active antiretroviral therapy 5 1996 1997 10 25 43 45 35 metabolism 50 copies/ml lipodystrophy [fat redistribution syndrome] lactic acidosis
More informationDidactic Series. Lipohypertrophy in HIV
Didactic Series Lipohypertrophy in HIV Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic August 14th, 2014 ACCREDITATION STATEMENT: University of California, San Diego School
More informationHLA-Bw4 Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after Initiation of. antiretroviral therapy.
BRIEF REPORT HIV/AIDS HLA-Bw4 Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after Initiation of Antiretroviral Therapy Andri Rauch, 1,7 David Nolan, 7 Hansjakob Furrer, 1 Elizabeth McKinnon,
More informationZurich Open Repository and Archive
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2010 Incidence and risk factors for chronic elevation of alanine aminotransferase
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Effect of Antiretroviral Therapy on Viral Load, CD4 Cell Count, and Progression to Acquired Immunodeficiency Syndrome in a Community Human Immunodeficiency Virus Infected Cohort
More informationPredictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study
Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study Marcel Wolbers a, Milos Opravil b, Viktor von Wyl b, Bernard Hirschel c,
More informationAssociations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study
Open Forum Infectious Diseases MAJOR ARTICLE Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study Cornelia Bayard, 1 Bruno Ledergerber, 1 Markus Flepp,
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationThe role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy
Journal of Antimicrobial Chemotherapy (2008) 62, 234 245 doi:10.1093/jac/dkn191 Advance Access publication 14 May 2008 The role of efavirenz compared with protease inhibitors in the body fat changes associated
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationA Genetic Test to Screen for Abacavir Hypersensitivity Reactions
The Future of Pharmacogenetics in HIV Clinical Care A Genetic Test to Screen for Abacavir Hypersensitivity Reactions Evan Collins & Misty Bath CANAC/ACIIS 15 th Annual Conference Vancouver, BC April 2007
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationLong-Term Evaluation of T-Cell Subset Changes After Effective Combination Antiretroviral Therapy During Asymptomatic HIV-Infection
JAIDS Journal of Acquired Immune Deficiency Syndromes 27:266 271 2001 Lippincott Williams & Wilkins, Inc., Philadelphia Long-Term Evaluation of T-Cell Subset Changes After Effective Combination Antiretroviral
More informationORIGINAL INVESTIGATION. CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years
CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years The Swiss HIV Cohort Study ORIGINAL INVESTIGATION Gilbert R. Kaufmann, MD; Luc
More informationD:A:D Study Teaching Material
D:A:D Study Teaching Material Data Collection of Adverse events of anti-hiv Drugs (D:A:D) study December 2012 - CHIP Background The D:A:D Study, is a prospective cohort study (collaboration) initiated
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Treatment Modification in Human Immunodeficiency Virus Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008 Luigia Elzi, MD, MSc; Catia Marzolini,
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationHigher Risk of Hyperglycemia in HIV-Infected Patients Treated with Didanosine Plus Tenofovir
6131_06_p333-337 4/5/06 10:28 AM Page 333 AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 22, Number 4, 2006, pp. 333 337 Mary Ann Liebert, Inc. Higher Risk of Hyperglycemia in HIV-Infected Patients Treated
More informationAntiretroviral therapy (ART) has led to a substantial
EPIDEMIOLOGY AND SOCIAL SCIENCE Correlates of Self-Reported Nonadherence to Antiretroviral Therapy in HIV-Infected Patients The Swiss HIV Cohort Study Tracy R. Glass, MSc,* Sabina De Geest, PhD, Rainer
More informationThe impact of antiretroviral drugs on Cardiovascular Health
The impact of antiretroviral drugs on Cardiovascular Health José López-Sendón Hospital Universitario La Paz. IdiPaz Madrid. Spain Research grants and honoraria from (research committees, clinical trials,
More informationA Comparison of Initial Antiretroviral Therapy in the Swiss HIV Cohort Study and the Recommendations of the International AIDS Society-USA
A Comparison of Initial Antiretroviral Therapy in the Swiss HIV Cohort Study and the Recommendations of the International AIDS Society-USA Gilles Wandeler 1,2 *, Olivia Keiser 2, Bernard Hirschel 3, Huldrych
More informationUniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study
Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study Cornelia Junghans a, Nicola Low a, Philip Chan a, Anne Witschi b,c,
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationVitamin D Deficiency in HIV: A Shadow on Long-Term Management?
AIDS Rev. 2014;16:59-74 (Supplementary Data) Vitamin D Deficiency in HIV: A Shadow on Long-Term Management? Chloe Orkin, et al.: Vitamin D deficiency in HIV (Supplementary Data) Chloe Orkin 1, David A.
More informationModeling the Influence of APOC3, APOE, and TNF Polymorphisms on the Risk of Antiretroviral Therapy Associated Lipid Disorders
MAJOR ARTICLE Modeling the Influence of APOC3, APOE, and TNF Polymorphisms on the Risk of Antiretroviral Therapy Associated Lipid Disorders Philip E. Tarr, 1 Patrick Taffé, 3 Gabriela Bleiber, 2 Hansjakob
More informationGynecologic diseases are more frequent in HIV-infected
CLINICAL SCIENCE Frequency of Gynecologic Follow-Up and Cervical Cancer Screening in the Swiss HIV Cohort Study Olivia Keiser, MSc,* Begoña Martinez de Tejada, MD, Dorothea Wunder, MD, Caroline Chapuis-Taillard,
More informationLiver Toxicity in Epidemiological Cohorts
SUPPLEMENT ARTICLE Liver Toxicity in Epidemiological Cohorts Stephen Becker Pacific Horizon Medical Group, San Francisco, California Hepatotoxicity has been demonstrated to be associated with antiretroviral
More informationNon-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy
CONCISE COMMUNICATION Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy Jerry Polesel a, Gary M. Clifford b, Martin Rickenbach c, Luigino
More informationLong-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study Jonathan A C Sterne, Miguel A Hernán, Bruno Ledergerber, Kate Tilling, Rainer Weber, Pedram
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationThe Lipid-Lowering Efficacy of Switching Within Non-Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients
American Journal of Infectious Diseases 4 (2): 147-151, 2008 ISSN 1553-6203 2008 Science Publications The Lipid-Lowering Efficacy of Switching Within Non-Nucleoside Reverse Transcriptase Inhibitors in
More informationJ Acquir Immune Defic Syndr Volume 57, Number 1, May 1, 2011
CLINICAL SCIENCE Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationWho is affected in Switzerland? The epidemiologist s point of view
Who is affected in Switzerland? The epidemiologist s point of view Roger Kouyos Division of Infectious Diseases and Hospital Epidemiology, USZ Institute of Medical Virology, University of Zurich Overview
More informationIschemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection
HIV/AIDS MAJOR ARTICLE Ischemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection Max H. David, 1,3 Richard Hornung, 2 and Carl J. Fichtenbaum 1 1 Department of Medicine, Division
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationefigure 1: Process of identification and selection of studies for inclusion in the review
efigure 1: Process of identification and selection of studies for inclusion in the review 1 efigure 2: Publication bias in studies reporting incidence rate of diabetes mellitus in ART-experienced global
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationResearch Article Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors
Hindawi BioMed Research International Volume 2017, Article ID 7481597, 14 pages https://doi.org/10.1155/2017/7481597 Research Article Metabolic Disorders in HIV-Infected Adolescents Receiving Protease
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationJean Mayer US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, 2 Tufts New England Medical Center, 3
HIV/AIDS MAJOR ARTICLE CD4 + Cell Count, Viral Load, and Highly Active Antiretroviral Therapy Use Are Independent Predictors of Body Composition Alterations in HIV-Infected Adults: A Longitudinal Study
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More informationAssessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study
J Antimicrob Chemother 2015; 70: 3323 3331 doi:10.1093/jac/dkv257 Advance Access publication 11 September 2015 Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationANTIRETROVIRAL TOXICITY Strategies for prevention and treatment
ANTIRETROVIRAL TOXICITY Strategies for prevention and treatment Francisco Antunes Professor da Faculdade de Medicina da Universidade de Lisboa e Director do Serviço de Doenças Infecciosas do Hospital de
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationSupplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.
Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationOnce-a-Day Highly Active Antiretroviral Therapy: A Systematic Review
HIV/AIDS MAJOR ARTICLE Once-a-Day Highly Active Antiretroviral Therapy: A Systematic Review Javier Ena and Francisco Pasquau HIV Unit, Department of Internal Medicine, Marina Baixa Hospital, Villajoyosa,
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationNational review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naïve patients
HIV Medicine (2007), 8, 186 191 ORIGINAL RESEARCH r 2007 British HIV Association National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naïve patients
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Rough K, Seage GR III, Williams PL, et al. Birth outcomes for
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Atazanavir () Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationHighly active antiretroviral therapy (HAART) has dramatically
HIV Re p o r t s Recovery From Lipodystrophy in HIV infected Children After Substitution of Stavudine With Zidovudine in a n-nucleoside Reverse Transcriptase Inhibitor based Antiretroviral Therapy Linda
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More informationDiagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection
RESEARCH ARTICLE Open Access Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection Jörg Schüpbach 1*, Leslie R Bisset 1, Martin D Gebhardt 2, Stephan Regenass 3, Philippe
More informationGilbert Syndrome and the Development of Antiretroviral Therapy Associated
MAJOR ARTICLE Gilbert Syndrome and the Development of Antiretroviral Therapy Associated Hyperbilirubinemia Margalida Rotger, 1 Patrick Taffé, 2 Gabriela Bleiber, 1 Huldrych F. Günthard, 3 Hansjakob Furrer,
More informationDifferences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006
13th Conference on Retroviruses and Opportunistic Infections Denver, CO, USA. February 5-9, 2006 Poster Number 777 Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir
More informationORIGINAL INVESTIGATION. A Critical Assessment of the Prognostic Value of HIV-1 RNA Levels and CD4 + Cell Counts in HIV-Infected Patients
ORIGINAL INVESTIGATION A Critical Assessment of the Prognostic Value of HIV- RNA Levels and CD + Cell Counts in HIV-Infected Patients Sabine Yerly, MS; Thomas V. Perneger, MD, PhD; Bernard Hirschel, MD;
More informationTenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study
Antiviral Therapy 12:1165 1173 Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study Christoph A Fux 1 *, Mathew Simcock 2,3, Marcel Wolbers
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationIncidence and Outcome of Progressive Multifocal Leukoencephalopathy over 20 Years of the Swiss HIV Cohort Study
MAJOR ARTICLE HIV/AIDS Incidence and Outcome of Progressive Multifocal Leukoencephalopathy over 20 Years of the Swiss HIV Cohort Study Nina Khanna, 1,2,a Luigia Elzi, 1,a Nicolas J. Mueller, 3 Christian
More informationAntiviral Therapy 2013; 18: (doi: /IMP2329)
Antiviral Therapy 2013; 18:213 219 (doi: 10.3851/IMP2329) Original article Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the
More informationAntiviral Therapy 11:
Antiviral Therapy 11:305 314 A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off? Mathew Simcock
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationPUBLIC HEALTH. HIV-infected patients HIV-infection toxicity adverse events virologic failure antiretroviral therapy. Key words:
e-issn 1643-3750 DOI: 10.12659/MSM.889283 Received: 2013.04.14 Accepted: 2013.05.14 Published: 2013.06.21 Toxicity-related antiretroviral drug treatment modifications in individuals starting therapy: A
More informationRenal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
Chua et al. AIDS Research and Therapy 2012, 9:19 SHORT REPORT Open Access Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort Arlene C Chua 1*, Ryan M Llorin 1, Kelvin Lai
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationRilpivirine use in the Swiss HIV cohort study: a prospective cohort study
Sculier et al. BMC Infectious Diseases (2017) 17:476 DOI 10.1186/s12879-017-2579-2 RESEARCH ARTICLE Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study Open Access Delphine Sculier
More informationAntiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationTitle: Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
Title: Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy? Author(s): David Nolan Source: Drug Safety. 28.12 (Dec. 2005): p1069. Document Type: Article Full Text: COPYRIGHT
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationBecause accurate and reproducible phenotypic susceptibility
BRIEF REPORT: CLINICAL SCIENCE Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility Assays Jie Zhang, MS,* Soo-Yon Rhee, MS,* Jonathan Taylor, PhD, and
More informationAntiviral Therapy 13:77 85
Original article Antiviral Therapy 13:77 85 Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients Tracy
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationTransient viral load increases in HIV-infected children in the UK and Ireland: what do they mean?
Transient viral load increases in HIV-infected children in the UK and Ireland: what do they mean? Katherine J Lee 1 *, Delane Shingadia 2, Deenan Pillay 3, A Sarah Walker 1, Andrew Riordan 4, Esse Menson
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More information